Stocks Health care ALVO
NASDAQ · Health careAlvotech (ALVO)
Alvotech reported revenue of $586.3M in fiscal 2025, up 19.7% from a year earlier. Net income was $27.9M, a net margin of 4.8%. In fiscal 2025 capital spending exceeded operating cash flow by $114.7M. At December 31, 2025 it held $172.4M in cash against $1.3B of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 31, 2026.
Key facts about Alvotech
- Net worth
- Alvotech has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of -$284.5M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $586.3M (+19.7% year on year), with net income of $27.9M.
- Cash flow
- In fiscal 2025 operations used $50.2M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 31, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Alvotech does
Alvotech is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALVO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $586.3M | $27.9M | $0.10 | -$114.7M |
| 2024 | $489.7M | -$231.9M | -$0.87 | -$290.5M |
| 2023 | $91.4M | -$551.7M | -$2.43 | -$345.4M |
| 2022 | $83M | -$513.6M | -$2.60 | -$350.3M |
| 2022 | $36.8M | -$101.5M | -$0.92 | -$248.6M |
| 2020 | $66.6M | -$170M | -$1.82 | -$81.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ALVO ranks in Health care
Latest SEC filings
What Alvotech has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 20, 2026
- October 14, 2026
- October 7, 2026
- October 5, 2026
- August 31, 2026
- August 21, 2026
- August 19, 2026
- July 29, 2026
- July 1, 2026
- June 30, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Alvotech did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns ALVO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Aztiq Pharma Partners S.à r.l.13D, may seek influence with 3 related filers | 33.5% | July 3, 2024 |
| Aztiq Pharma Partners S.a r.l.13D, may seek influence with 4 related filers | 33.3% | March 12, 2026 |
| Celtic Holdings S.C.A.13D, may seek influence with 1 related filers | 27.5% | June 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 72 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rubric Capital Management LP | 15,677,093 | new |
| Millennium Management LLC | 4,263,644 | +2,141,048 |
| Bracebridge Capital, LLC | 4,038,637 | +1,333,333 |
| Vanguard Capital Management LLC | 3,689,612 | +279,165 |
| Farallon Capital Management, L.L.C. | 2,859,675 | +2,660,000 |
| Citadel Advisors LLC | 1,728,002 | new |
| BlackRock, Inc. | 1,327,282 | +82,087 |
| Littlejohn & Co LLC | 1,318,534 | 0 |
| Vanguard Fiduciary Trust Co | 998,597 | +24,369 |
| Legal & General Group Plc | 696,048 | +191,588 |
| Morgan Stanley | 670,041 | +426,764 |
| Royce & Associates LP | 558,144 | new |
| Jpmorgan Chase & Co | 529,689 | +25,488 |
| Sona Asset Management (US) LLC | 360,000 | new |
| Geode Capital Management, LLC | 297,261 | -26,938 |
| UBS Group AG | 253,482 | -68,675 |
| Hudson Bay Capital Management LP | 238,107 | new |
| VANGUARD ASSET MANAGEMENT, Ltd | 151,935 | 0 |
| Lighthouse Investment Partners, LLC | 125,000 | new |
| Oaktree Capital Management LP | 97,982 | -142,056 |
Insiders
Questions about ALVO
What does Alvotech do?
Alvotech is a company in the Health care sector, listed on NASDAQ as ALVO. Its shares trade on NASDAQ under the ticker ALVO.
What is Alvotech's net worth?
Alvotech has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of -$284.5M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Alvotech profitable?
Yes. In fiscal 2025 it reported net income of $27.9M on revenue of $586.3M, a net margin of 4.8%.
How much revenue does Alvotech make?
In fiscal 2025 Alvotech reported revenue of $586.3M. That is 19.7% more than a year earlier.
When did Alvotech last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from October 20, 2026.
Similar companies
Compare ALVO with
Follow ALVO
Get an email when Alvotech files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Alvotech tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.